research News

Aurora, Colorado – New research overseen by University of Colorado Cancer Center member Rebecca Schweppe, PhD, could lead to improved treatment for people with thyroid cancer characterized by a mutation in the BRAF gene, a mutation also responsible for some types of melanoma, colorectal cancer, leukemia, lymphoma, and ovarian cancer....
Melbourne, Australia – In the study led by the Peter Doherty Institute for Infection and Immunity (Doherty Institute) and published in Science Immunology, the researchers found that CD4+ T cells, traditionally called ‘helper T cells’ for their role in aiding the activation of other immune cells, are remarkably effective in...
Montreal, Canada – A common stomach bacteria found in two thirds of the world population may be linked to a higher risk of Alzheimer’s disease, new research suggests. The study, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, investigated whether a clinically apparent Helicobacter pylori (H. pylori)...
BUFFALO, NY – A new review was published in Oncotarget’s Volume 15 on August 2, 2024, entitled, “Targeting WNT5B and WNT10B in osteosarcoma.” As noted in the abstract of this paper, WNT signaling regulates osteosarcoma proliferation. There is, however, controversy in the field of osteosarcoma as to whether WNT signaling...
Cellular immunotherapies have so far not been very effective against non-Hodgkin’s lymphoma. A team led by Armin Rehm of the MDC has discovered a possible reason. As the they describe in “Cell Reports”, this cancer induces changes in the large blood vessels through which immune cells normally migrate to the lymph...
BUFFALO, NY – A new editorial paper was published in Oncoscience (Volume 11) on April 25, 2024, entitled, “Therapeutic opportunities for hypermutated urothelial carcinomas beyond immunotherapy.” In this new editorial, researcher Ioannis A. Voutsadakis from Sault Area Hospital and Northern Ontario School of Medicine discusses tumor mutation burden (TMB)—a novel...
An international, open-label Phase 3 study, co-led by Susanna McColley, MD, from Ann & Robert H. Lurie Children’s Hospital of Chicago, found that a regimen of three drugs (elexacaftor/tezacaftor/ivacaftor) that targets the genetic cause of cystic fibrosis was safe and effective in 6-11-year-olds with at least one copy of F508del...
DUBLIN, Ireland — Theravance Biopharma Inc. today announced results from the Phase 4 PIFR-2 study of YUPELRI® (revefenacin) inhalation solution, the only once-daily, nebulized long-acting muscarinic antagonist (LAMA) approved in the U.S. for maintenance treatment of COPD. The PIFR-2 study aimed to demonstrate greater improvement in lung function for YUPELRI...